Yeda Research and Develpment & Co. Ltd

Other

Avraham Ben-Nun

Nicole Kerlero De Rosbo

Paul Gregor Sappler

Pinchas Burstein

Gregor Paul Sappler

Agents selected from: (i) a C-Calkyl ester of a saturated or cis-unsaturated C-Cfatty acid; (ii) a monoester or polyester of a polyol having at least four hydroxy groups with a saturated or cis-unsaturated C-Cfatty acid or an anhydro derivative thereof; (iii) a monoester or polyester of a mono-, di- or poly-saccharide with a saturated or cis-unsaturated C-Cfatty acid; (iv) an amide of a saturated or cis-unsaturated C-Cfatty acid with an aliphatic or aromatic amine or with an amino acid, peptide, protein or aminosaccharide; and (v) combinations of any of (i) to (iv), can be used for treatment of autoimmune diseases and other immune-associated inflammatory disorders. Preferred agents are ethyl oleate and mannide monooleate or a combination thereof.

Use of esters of long-chain fatty acids for treatment of autoimmune diseases

Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clusters (hereinafter IEC) of autoantigen(s) related to a specific autoimmune disease, wherein said at least two IECs may be derived from a sole autoantigen or from at least two different autoantigens related to said autoimmune disease, and polypeptides encoded thereby, can be used for the treatment and the diagnosis of autoimmune diseases such as multiple sclerosis (MS), insulin-dependent diabetes mellitus (IDDM), rheumatoid arthritis (RA), myasthenia gravis (MG) and uveitis.

Synthetic human genes and polypeptides and their use in the treatment of autoimmune diseases

Synthetic unaltered and altered peptides comprising sequences of at least one immunogenic epitope cluster (IEC) of at least one human autoantigen related to multiple sclerosis (MS) and at least one nonameric core sequence which fits into the MS-relevant HLA-DR/DQ molecule and is flanked by 2-5 amino acids at its N- and C-termini, are provided. The alteration is preferably by substituting 1 to 3 TCR contact residues by Ala. The autoantigen is preferably MOG, MBP, OSP, MOBP and PLP. Polypeptides comprising at least two such peptides of a sole autoantigen or at least one peptide of two different autoantigens, and synthetic genes encoding them, are also provided, as well as pharmaceutical compositions for treatment and diagnostic of MS.

Synthetic peptides and DNA sequences for treatment of multiple sclerosis

12-kDa protein derived from M. Tuberculosis useful for treatment of

Pharmaceutical compositions for the treatment of autoimmune diseases

Growing community of inventors

Yavne, Israel

Avraham Ben-Nun